List of Naloxone Hydrochloride (autoinjector) drug patents

Naloxone Hydrochloride (Autoinjector) is owned by Kaleo Inc.

Naloxone Hydrochloride (Autoinjector) contains Naloxone Hydrochloride.

Naloxone Hydrochloride (Autoinjector) has a total of 20 drug patents out of which 0 drug patents have expired.

Naloxone Hydrochloride (Autoinjector) was authorised for market use on 28 February, 2022.

Naloxone Hydrochloride (Autoinjector) is available in solution;intramuscular, subcutaneous dosage forms.

Naloxone Hydrochloride (Autoinjector) can be used as use of a delivery device to administer a dose of naloxone, use of a delivery device to deliver a dose of naloxone.

The generics of Naloxone Hydrochloride (Autoinjector) are possible to be released after 24 May, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 5 months from now)

US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(1 year, 7 months from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(1 year, 9 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(1 year, 11 months from now)

US11590286 KALEO INC Devices, systems and methods for medicament delivery
Dec, 2026

(3 years from now)

US7947017 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2028

(4 years from now)

US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US9814838 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US10143792 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
May, 2031

(7 years from now)

Do you want to check out NALOXONE HYDROCHLORIDE (AUTOINJECTOR) patents from before 2022?

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents

101

United States

19

Canada

18

United Kingdom

11

Australia

11

European Union

10

Japan

6

China

6

Mexico

5

Israel

4

New Zealand

3

Spain

3

Denmark

2

Poland

2

Hong Kong

2

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic